- A researcher grows a culture of human cells in a medium containing L-aspartate where the amino group nitrogen is labeled with 15N. After several cell divisions, purine and pyrimidine nucleotides are isolated. Where would the 15N label be predominantly found?
Answer: At position N1 of the purine ring and position N1 of the pyrimidine ring.
When you encounter questions about nitrogen incorporation from labeled amino acids, focus on the biosynthetic pathways for nucleotide synthesis and which specific nitrogens come from which precursors.
L-aspartate serves as a crucial nitrogen donor in nucleotide biosynthesis. In purine synthesis, aspartate's amino nitrogen is incorporated at position N1 through the action of adenylosuccinate synthetase, which adds aspartate to IMP (inosine monophosphate) during the conversion to AMP. In pyrimidine synthesis, aspartate condenses with carbamoyl phosphate in the first step catalyzed by aspartate transcarbamoylase, contributing its amino nitrogen to what becomes position N1 of the pyrimidine ring.
Answer A correctly identifies both incorporation sites: N1 in purines and N1 in pyrimidines receive nitrogen from aspartate's amino group. Answer B is incorrect because N7 in purines comes from glycine, not aspartate, and while N3 in pyrimidines does contain nitrogen, it derives from carbamoyl phosphate (ultimately from glutamine), not aspartate. Answer C wrongly places the purine label at N3, which actually comes from glutamine during the initial steps of purine ring formation. Answer D incorrectly suggests dual purine labeling and no pyrimidine incorporation—N9 comes from glycine, and pyrimidines definitely incorporate aspartate nitrogen.
Remember that amino acid precursors have specific, predictable incorporation patterns in nucleotide synthesis. Aspartate consistently contributes to N1 positions in both purine and pyrimidine rings, making this a reliable pattern to memorize for biochemistry exams.
- A cell line deficient in thymidine kinase (TK-) is cultured in medium containing BrdU (5-bromodeoxyuridine) and exhibits normal growth and DNA synthesis. However, when the same cells are cultured with BrdU in the presence of aminopterin (folate antagonist), they show severe growth inhibition. Which of the following best explains this observation?
Answer: BrdU can substitute for thymidine via alternative kinases, but aminopterin blocks the de novo pathway that normally compensates for TK deficiency
TK-deficient cells can normally survive because they can synthesize dTTP via the de novo pathway (dUMP → dTMP via thymidylate synthase, then phosphorylation to dTTP). BrdU can be phosphorylated by alternative kinases (like deoxyuridine kinase) to BrdUTP, which can substitute for dTTP in DNA synthesis. However, aminopterin blocks folate-dependent reactions, including the thymidylate synthase reaction that converts dUMP to dTMP. This forces the cells to rely entirely on salvage pathways for thymidine nucleotides. Since these cells lack thymidine kinase and BrdU phosphorylation by alternative enzymes may be less efficient, they cannot maintain adequate dTTP pools. A is incorrect because aminopterin doesn't prevent BrdU metabolism. B is wrong because alternative kinases can phosphorylate BrdU. D overstates the specificity of the interaction.
- In a study of pyrimidine metabolism, researchers observe that cells treated with N-phosphonacetyl-L-aspartate (PALA), an inhibitor of aspartate transcarbamoylase, can be rescued by adding uridine to the medium, but not by adding uracil or orotic acid. Based on these results, which of the following conclusions about pyrimidine salvage pathways is most accurate?
Answer: The cells lack functional enzymes for converting uracil or orotic acid to UMP, but retain the ability to phosphorylate uridine
The experimental results suggest that these particular cells have functional uridine kinase (which can convert uridine to UMP directly) but lack or have deficient uracil phosphoribosyltransferase (needed to convert uracil + PRPP to UMP) and/or orotate phosphoribosyltransferase (needed to convert orotic acid + PRPP to OMP). This would explain why only uridine can rescue the PALA-induced pyrimidine starvation. A is incorrect because it assumes all enzymes are present but differ in activity. C is wrong because PALA inhibits aspartate transcarbamoylase, not PRPP synthesis, and if PRPP were depleted, uridine phosphorylation might also be affected. D focuses on transport rather than enzymatic conversion, and transport differences alone wouldn't explain the complete inability to use uracil or orotic acid.
- Researchers studying purine metabolism in different tissues find that brain tissue shows much higher APRT (adenine phosphoribosyltransferase) activity relative to HPRT activity compared to liver tissue. Given the metabolic characteristics of neural tissue, which of the following best explains this tissue-specific difference in salvage enzyme expression?
Answer: Brain tissue relies heavily on adenine salvage to maintain ATP pools for high energy demands
Brain tissue has very high energy demands and limited capacity for de novo purine biosynthesis compared to metabolically active tissues like liver. Neural tissue relies heavily on salvage pathways to maintain purine nucleotide pools, particularly for ATP synthesis needed for energy metabolism. Higher APRT activity ensures efficient recycling of adenine to AMP, which can then be phosphorylated to ATP. B is incorrect because neurotransmitter synthesis doesn't primarily depend on adenine nucleotides. C is wrong because the blood-brain barrier doesn't selectively restrict purine bases. D is incorrect because brain tissue has relatively low DNA synthesis rates compared to other tissues.
- Orotic aciduria is an autosomal recessive disorder caused by a defect in UMP synthase, a bifunctional enzyme catalyzing the final two steps of de novo pyrimidine synthesis. Patients excrete large amounts of orotic acid and suffer from megaloblastic anemia. Which of the following would be the most effective treatment for this condition?
Answer: Administration of uridine, which can be salvaged to UMP, bypassing the enzymatic block and providing pyrimidines.
The most effective treatment is to bypass the metabolic block. Administering uridine allows cells to use the salvage enzyme uridine kinase to phosphorylate it to UMP. This provides the necessary pyrimidine nucleotides for nucleic acid synthesis, correcting the anemia. Furthermore, the resulting downstream products (like UTP) will feedback-inhibit carbamoyl phosphate synthetase II, the first step of the pathway, which reduces the production and excretion of the precursor orotic acid.
- The chemotherapeutic agent 5-fluorouracil (5-FU) is a pro-drug that is converted in the cell to 5-fluorodeoxyuridine monophosphate (FdUMP). FdUMP is a potent mechanism-based inhibitor. Which metabolic process is the primary target of FdUMP, leading to cell cycle arrest?
Answer: The methylation of deoxyuridine monophosphate (dUMP) to form deoxythymidine monophosphate (dTMP).
When you encounter questions about mechanism-based inhibitors in chemotherapy, focus on understanding how the drug mimics natural substrates to disrupt essential cellular processes. The key is identifying which enzyme gets "fooled" by the structural similarity.
5-fluorodeoxyuridine monophosphate (FdUMP) is a fluorinated analog of deoxyuridine monophosphate (dUMP) that specifically targets thymidylate synthase, the enzyme responsible for converting dUMP to dTMP (deoxythymidine monophosphate). This methylation reaction is crucial because dTMP is the sole source of thymidine nucleotides needed for DNA synthesis. FdUMP forms an irreversible covalent complex with thymidylate synthase, permanently blocking the enzyme and depleting the cell's dTMP pool, which leads to cell cycle arrest during S phase.
Option A is incorrect because FdUMP doesn't affect pyrimidine salvage pathways or PRPP utilization. Option B is wrong because ribonucleotide reductase converts ribonucleoside diphosphates to deoxyribonucleoside diphosphates - a different step entirely. Option C incorrectly identifies carbamoyl phosphate synthetase II in de novo pyrimidine synthesis, which isn't FdUMP's target.
Option D correctly identifies the methylation of dUMP to dTMP as FdUMP's primary target, making this the right answer.
Remember that fluorinated nucleotide analogs often work by mimicking natural substrates closely enough to bind their target enzymes, but with enough structural difference to disrupt normal function. Focus on understanding the specific enzymatic step being blocked rather than memorizing drug names.
- The de novo biosynthetic pathways for purines and pyrimidines differ fundamentally in their assembly strategy. Which statement correctly describes a key distinction between these two pathways?
Answer: The pyrimidine ring is first synthesized as the base orotate before attachment to PRPP, whereas the purine ring is assembled stepwise upon the ribose.
Understanding nucleotide biosynthesis requires recognizing that purines and pyrimidines follow completely opposite assembly strategies. This fundamental difference affects how each pathway constructs the nitrogenous base and attaches it to the ribose sugar.
The correct answer is D because it accurately describes this key distinction. In pyrimidine synthesis, the six-membered ring is first assembled as the free base orotate through a series of reactions beginning with carbamoyl phosphate and aspartate. Only after orotate is fully formed is it transferred to PRPP (phosphoribosyl pyrophosphate) to create the nucleotide. Purine synthesis works in reverse - the purine ring is built atom by atom directly onto PRPP, with the ribose sugar serving as the foundation throughout the entire process.
Choice A reverses the carbamoyl phosphate usage - pyrimidines use carbamoyl phosphate as their starting material, not purines. Choice B completely inverts the actual mechanism, incorrectly stating that purines are made as free bases first. Choice C is wrong about cellular location - both pathways occur primarily in the cytosol, though some purine synthesis enzymes are found in mitochondria.
Remember this contrast with a simple rule: "Pyrimidines make the ring first, then attach; purines attach first, then make the ring." This assembly difference explains why pyrimidine synthesis is more straightforward and why purine synthesis requires more complex regulation. Focus on this fundamental distinction when studying nucleotide metabolism.
- In an experimental study of nucleotide biosynthesis, researchers measure the incorporation of 32P-labeled phosphate into cellular nucleotides under different conditions. They find that cells treated with azaserine (glutamine analog) show dramatically reduced incorporation into purines but normal incorporation into pyrimidines. Which aspect of nucleotide biosynthesis best explains this selective effect?
Answer: Pyrimidine synthesis uses aspartate as the nitrogen source, while purine synthesis depends on multiple glutamine-requiring steps
Azaserine is a glutamine analog that inhibits glutamine-utilizing enzymes. De novo purine synthesis requires glutamine at multiple steps: the initial step (PRPP + glutamine), the conversion of formylglycinamide ribonucleotide to formylglycinamidine ribonucleotide, and in the conversion of IMP to GMP. In contrast, pyrimidine synthesis uses aspartate as the primary nitrogen donor in the formation of carbamoyl aspartate, and doesn't rely heavily on glutamine-dependent steps. A is incorrect because azaserine doesn't specifically target adenylosuccinate synthetase. C is partially correct but incomplete - it's not just the committed step but multiple steps in purine synthesis that require glutamine. D is wrong because azaserine doesn't primarily affect PRPP synthesis, and PRPP is used in both pathways.
- Methotrexate is an anticancer drug that acts as a competitive inhibitor of dihydrofolate reductase (DHFR). A rapidly dividing cancer cell culture is treated with an effective dose of methotrexate. Which of the following metabolic consequences is the most direct cause of the drug's cytotoxic effect on these cells?
Answer: An accumulation of dUMP and a corresponding inability to synthesize deoxythymidine monophosphate (dTMP).
Methotrexate inhibits dihydrofolate reductase (DHFR), preventing the regeneration of tetrahydrofolate (THF) from dihydrofolate (DHF). The enzyme thymidylate synthase requires the THF derivative N⁵,N¹⁰-methylenetetrahydrofolate to convert dUMP to dTMP. By depleting the THF pool, methotrexate effectively starves thymidylate synthase of its cofactor, causing dUMP to accumulate and halting dTMP synthesis. The lack of dTMP, a necessary precursor for DNA replication, is the primary cause of cytotoxicity in rapidly dividing cells.
- In the de novo synthesis of purine nucleotides, the conversion of inosine monophosphate (IMP) to adenosine monophosphate (AMP) requires GTP as an energy source, while the conversion of IMP to guanosine monophosphate (GMP) requires ATP. What is the primary regulatory advantage of this reciprocal energy requirement?
Answer: It provides a mechanism to balance the intracellular pools of ATP and GTP, as the synthesis of one requires a high concentration of the other.
This reciprocal relationship is a key mechanism for maintaining a balance between the cellular pools of adenine and guanine nucleotides. When the concentration of ATP is high, it signals that the cell has sufficient adenine nucleotides and can 'afford' to synthesize GMP (using ATP as the energy source). Conversely, when GTP is abundant, it drives the synthesis of AMP. This ensures that a deficiency in one purine does not lead to an unchecked synthesis of the other, thereby maintaining the proper ratio required for nucleic acid synthesis and cellular signaling.
- A researcher is studying nucleotide metabolism in cancer cells and observes that treatment with methotrexate (a dihydrofolate reductase inhibitor) can be partially rescued by adding thymidine to the culture medium. However, the same rescue is not observed when only thymine is added. Which of the following best explains this differential rescue effect?
Answer: Thymidine salvage bypasses the folate-dependent step in dTMP synthesis, while thymine salvage still requires tetrahydrofolate cofactors
Methotrexate inhibits dihydrofolate reductase, depleting the cell of tetrahydrofolate cofactors needed for one-carbon transfer reactions. In de novo dTMP synthesis, thymidylate synthase requires N5,N10-methylene-THF to convert dUMP to dTMP. When thymidine is added, it can be phosphorylated directly by thymidine kinase to dTMP, bypassing the folate-dependent synthetic step entirely. However, thymine salvage requires thymine phosphoribosyltransferase to form TMP, which must then be converted to dTMP through pathways that may still involve folate-dependent steps. A is incorrect because both thymine and thymidine can enter cells. B misrepresents the enzyme kinetics and names. C is wrong because thymine phosphoribosyltransferase doesn't require folate cofactors directly.
- Ribonucleotide reductase (RNR) is subject to complex allosteric regulation. The enzyme has two types of allosteric sites: a specificity site and an overall activity site. How would a very high, non-physiological concentration of dATP affect the function of RNR?
Answer: It would bind to the overall activity site, causing a general inhibition of the enzyme and shutting down all dNTP production.
Ribonucleotide reductase is activated when ATP binds to its overall activity site. However, when dATP levels become very high, dATP displaces ATP from this site and acts as a potent general inhibitor of the enzyme. This is a crucial feedback mechanism that prevents the overproduction of deoxyribonucleotides, which can be mutagenic. While dATP also binds the specificity site to promote reduction of pyrimidines, its powerful inhibitory effect at the activity site overrides this function at high concentrations.
- A cell needs to produce one molecule of GMP. It can do so either via the de novo pathway starting from ribose-5-phosphate or via the salvage pathway using free guanine. Which statement provides the most accurate energetic comparison of these two routes?
Answer: The salvage pathway offers a significant energy saving by bypassing the multiple ATP- and GTP-dependent steps of de novo ring synthesis.
The de novo synthesis of a purine nucleotide like GMP is extremely energy-intensive, consuming multiple molecules of ATP and GTP, as well as precursor amino acids. The salvage pathway is a shortcut that recycles a pre-existing base. The key reaction, catalyzed by HGPRT, uses one molecule of PRPP. While the synthesis of PRPP from ribose-5-phosphate costs two ATP equivalents (ATP → AMP + PPi), this is far less than the total cost of building the entire purine ring from scratch. Thus, salvage pathways provide a major conservation of cellular energy.
